[1] CULP MB, SOERJOMATARAM I, EFSTATHIOU JA, et al. Recent global patterns in prostate cancer incidence and mortality rates[J]. Eur Urol, 2020, 77(1): 38. doi: 10.1016/j.eururo.2019.08.005
[2] 王茹月, 叶雨. PSA衍生指标诊断前列腺癌的研究进展[J]. 中华男科学杂志, 2019, 25(7): 655. doi: 10.13263/j.cnki.nja.2019.07.015
[3] 杨进益, 杨明州, 魏伟, 等. 前列腺癌发生发展的流行病学研究进展[J]. 临床泌尿外科杂志, 2017, 32(9): 721. doi: 10.13201/j.issn.1001-1420.2017.09.018
[4] 前列腺癌筛查中国专家共识(2021年版)[J]. 中国癌症杂志, 2021, 31(5): 435.
[5] ZHU Y, MO M, WEI Y, et al. Epidemiology and genomics of prostate cancer in Asian men[J]. Nat Rev Urol, 2021, 18(5): 282. doi: 10.1038/s41585-021-00442-8
[6] TCHIR D, FARAG M, SZAFRON M. Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data[J]. Can Urol Assoc J, 2020, 14(7): E319.
[7] CATALONA WJ. Prostate cancer screening[J]. Med Clin North Am, 2018, 102(2): 199. doi: 10.1016/j.mcna.2017.11.001
[8] DE LIMA MM, FILHO SSJ, TOBIAS-MACHADO M. Association between PSA and age in Macuxi ethnic population of the Brazilian Amazon forest region[J]. Res Rep Urol, 2018(10): 159.
[9] 张红双, 李杨亮, 陆佳. 急性前列腺炎患者血清前列腺特异性抗原的变化及其意义[J]. 蚌埠医学院学报, 2014, 39(5): 627. doi: 10.13898/j.cnki.issn.1000-2200.2014.05.045
[10] BAI X, JIANG Y, ZHANG X, et al. The Value of prostate-specific antigen-related indexes and imaging screening in the diagnosis of prostate cancer[J]. Cancer Manag Res, 2020, 12: 6821. doi: 10.2147/CMAR.S257769
[11] 朱刚, 张凯. 中国前列腺癌筛查的现状和挑战[J]. 山东大学学报(医学版), 2019, 57(1): 11.
[12] CAGLAYAN V, ONEN E, AVCI S, et al. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl[J]. Arch Ital Urol Androl, 2019, 90(4): 270. doi: 10.4081/aiua.2018.4.270
[13] TEMEL MC, EDIZ C, AKAN S, et al. Association of Gleason score with PSA values and serum testosterone levels measured prior to prostate biopsy[J]. J Coll Physicians Surg Pak, 2020, 30(4): 399. doi: 10.29271/jcpsp.2020.04.399
[14] WANG J, ABUDUREXITI M, SHAO N, et al. The U shape of prostate-specific antigen and prostate cancer-specific mortality in high-grade metastatic prostate adenocarcinoma[J]. Eur Urol Focus, 2020, 6(1): 53. doi: 10.1016/j.euf.2018.08.024
[15] 燕小朋, 张学珍, 梁姗. 经直肠超声引导下前列腺穿刺活检结合血清PSA早期诊断前列腺癌价值[J]. 蚌埠医学院学报, 2018, 43(5): 637.
[16] 余宗泽, 韩德军, 吴强. 前列腺特异性抗原4~10μg/L患者前列腺癌检出率及与年龄和病理分级的相关性分析[J]. 肿瘤预防与治疗, 2019, 32(6): 533. doi: 10.3969/j.issn.1674-0904.2019.06.011
[17] PAZETO CL, LIMA TFN, TRUZZI JC, et al. PSA kinetics before 40 years of age[J]. Int Braz J Urol, 2018, 44(6): 1114. doi: 10.1590/s1677-5538.ibju.2017.0710
[18] HE T, MULLINS CD. Age-related racial disparities in prostate cancer patients: a systematic review[J]. Ethn Health, 2017, 22(2): 184.
[19] TR R. Prostate cancer genetics: variation by race, ethnicity, and geography[J]. Semin Radiat Oncol, 2017, 27(1): 3.
[20] 黄考平, 温世和, 杨天. 血清PSA与良性前列腺增生临床病理的相关性研究[J]. 中国实用医药, 2019, 14(34): 66.
[21] 朱旋, 张忠民, 胡少炜, 等. 中老年男性非前列腺癌住院患者血清PSA及其相关指标的特点分析[J]. 现代泌尿生殖肿瘤杂志, 2018, 10(2): 98.
[22] 魏利军, 刘海, 吴永珍, 等. 綦江区前列腺癌健康筛查的临床意义[J]. 蚌埠医学院学报, 2016, 41(9): 1144.
[23] PINSKY PF, PROROK PC, YU K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years[J]. Cancer, 2017, 123(4): 592.
[24] DALL'ERA MA, DEVERE-WHITE R, RODRIGUEZ D, et al. Changing incidence of metastatic prostate cancer by race and age, 1988-2015[J]. Eur Urol Focus, 2019, 5(6): 1014.
[25] 郭振毅. F-PSA、VEGF和IGF-P水平联合检测在前列腺癌中的临床意义[J]. 数理医药学杂志, 2021, 34(5): 680.